Biome Australia Ltd · ASX:BIO
Biome Australia — Corporate Update (July 2026)
27 slides from Biome Australia's corporate update, Jul 27, 2026
Slide 1: International Markets: FY26 review and FY27 priorities
FY26 INVESTOR UPDATE International Markets FY26 review and FY27 priorities Prepared by Biome Australia Limited · July 2026 ASX: BIO
Slide 2: Disclaimer and forward-looking statements
IMPORTANT NOTICE Disclaimer and forward-looking statements This presentation is provided for information purposes only and should be read together with Biome Australia Limited’s ASX announcements and financial reports. Not financial advice Forward-looking statements Data and estimates This presentatio
Slide 3: Our Mission
OUR MISSION To prevent disease, improve health outcomes and quality of life, and make our products accessible to all. Biome Australia Limited · ASX: BIO
Slide 4: Proud to be B Corp certified
CERTIFIED B CORPORATION Proud to be B Corp certified Certified B Corporations are leaders in the global movement for an inclusive, equitable and regenerative economy by committing and demonstrating: ● Responsible social and environmental practices that benefit employees and the wider community ● A corp
Slide 5: About Biome Australia
COMPANY OVERVIEW About Biome Australia Clinically-proven, condition-specific probiotics, developed with world-leading microbiome research partners. Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven, condition-specific p
Slide 6: FY26 international performance
FY26 IN NUMBERS FY26 international performance Four markets contributing, with operating leverage beginning to show FY26 INT'L REVENUE INT'L GROSS MARGIN INT'L DISTRIBUTION INTERNATIONAL FTE APPROACHING POINTS BREAKEVEN approaching $1.8m ~68% ~2,000 12 breakeven +26% on FY25 7pp above domestic and g
Slide 7: The Australian model
THE AUSTRALIAN MARKET The Australian model Australia scaled from 100 to 7,500 points of sale in six years to become the #1 probiotic product in Australian pharmacy₁ (Biome Daily), on a practitioner-led, non-discounted model. The same model is now running across four international markets. AUSTRALIA
Slide 8: Category position in Australia
#1 IN AUSTRALIA / SCALING TO THE WORLD Category position in Australia Two #1 products in Australian pharmacy scan sales (FY26), on the platform to scale internationally in FY27. #1 #1 Flagship daily probiotic Children's immune health Biome Daily Probiotic Biome Daily Kids Probiotic The number one pr
Slide 9: Operating leverage emerging
OPERATING LEVERAGE Operating leverage emerging Revenue growth outpaced cost growth in FY26. Group gross profit of $1.21m at 68%, with net loss narrowing to $649k. FY26 GROUP PERFORMANCE · A$M $1.80m $1.82m The build phase is behind us Group gross profit $1,214k at a blended 68% margin; net loss narrow
Slide 10: Four active markets
GLOBAL FOOTPRINT Four active markets Independent demand across each market, with an optimised channel mix per jurisdiction. GROWING NH HUB SCALING LAUNCHING Canada United Kingdom Ireland New Zealand Fullscript & Ecotrend NH sales, marketing & Uniphar 18 → 40 stores ProPharma & Practitioner distribut
Slide 11: Canada
MARKET DEEP DIVE · CANADA / OPPORTUNITY Canada The largest international contributor, now deepening: five distribution partners across practitioner, pharmacy and health-food channels. GROWING PROBIOTICS MARKET CATEGORY GROWTH US$2.5bn ~13% p.a. 2023, Grand View Research CAGR to 2030 CHANNELS Practiti
Slide 12: Canada — execution
MARKET DEEP DIVE · CANADA / EXECUTION Canada — execution Deepening across channels: the practitioner platform anchored by Fullscript and Ecotrend, with pharmacy and health-food retail secured in FY26. PARTNERS & DISTRIBUTORS COMPETITORS — WHAT WE DO BETTER HOW WE SCALE Genestra ● Unlock Quebec marke
Slide 13: United Kingdom
MARKET DEEP DIVE · UNITED KINGDOM / OPPORTUNITY United Kingdom Our Northern Hemisphere hub: distribution, sales and marketing for the EU and Canada run from the UK, alongside a measured practitioner-in-clinic market. NH HUB HUB ROLE Sales · Marketing · Distribution run from the UK CHANNELS In-clinic
Slide 14: United Kingdom — execution
MARKET DEEP DIVE · UNITED KINGDOM / EXECUTION United Kingdom — execution A hub-first model: the UK team runs Northern Hemisphere operations, with the practitioner market served through specialist distributors. PARTNERS & DISTRIBUTORS COMPETITORS — WHAT WE DO BETTER HOW WE SCALE Symprove ● Run EU + Ca
Slide 15: Ireland
MARKET DEEP DIVE · IRELAND / OPPORTUNITY Ireland A strong long-term pharmacy market: 50% of Irish supplement sales still go through pharmacy. Five banner groups secured in FY26, more onboarding in FY27. SCALING REGISTERED PHARMACIES SUPPLEMENTS GROWTH 1,989 ~8% p.a. end-2024, PSI register Category t
Slide 16: Ireland — execution
MARKET DEEP DIVE · IRELAND / EXECUTION Ireland — execution A hybrid UK/Australian strategy: traditional marketing to grow pharmacy footprint, with GP and dentist detailing. No NHS plus a strong herbal-medicine tradition make Ireland well suited. PARTNERS & DISTRIBUTORS COMPETITORS — WHAT WE DO BETTE
Slide 17: New Zealand
MARKET DEEP DIVE · NEW ZEALAND / OPPORTUNITY New Zealand A foundation year. Practitioner base and ProPharma distribution in place; the Propharma wholesale pharmacy launch in Q4 FY26 is the near-term catalyst. LAUNCHING NATURAL HEALTH INDUSTRY PHARMACY UNIVERSE NZ$2.3bn ~1,100 Natural Health Products
Slide 18: New Zealand — execution
MARKET DEEP DIVE · NEW ZEALAND / EXECUTION New Zealand — execution Distribution established through ProPharma, corporate pharmacy launching through Green Cross in Q4 FY26. PARTNERS & DISTRIBUTORS COMPETITORS — WHAT WE DO BETTER HOW WE SCALE Clinicians ● Launch Green Cross corporate roll-out ProPharm
Slide 19: Pricing and margin architecture
PRICING POWER Pricing and margin architecture One global pricing architecture. Biome Daily Probiotic anchors a premium, non-discounted position in every market, in local currency. AUSTRALIA CANADA UK IRELAND NEW ZEALAND A$ 34.95 C$ 46.99 £ 29.95 € 36.95 NZ$ 39.95 Home market RRP Fullscript / retail,
Slide 20: Northern Ireland hub: gateway to mainland Europe
SUPPLY CHAIN / EU GATEWAY Northern Ireland hub: gateway to mainland Europe The TDS 3PL hub sits in Northern Ireland, supplying mainland Europe directly and serving the UK alongside. Northern Irish Advantage Located within the UK single market — with unique access to free trade within the EU. EU Nort
Slide 21: Onshore manufacturing - Specialty Probiotics Australia (SPA)
MANUFACTURING / THE STEP CHANGE Onshore manufacturing - Specialty Probiotics Australia (SPA) Australian onshore manufacturing under the June 2026 SPA agreement commences September 2026 — the step change that lets the international platform scale. Small-batch agility Faster and more Premium finish Low
Slide 22: Direct wholesale and e-scripts for practitioners
NEW INITIATIVE / BIOME B2B2C & eSCRIPT PORTAL Direct wholesale and e-scripts for practitioners Launching H1 FY27: a direct wholesale model and e-script portal that lets practitioners prescribe Biome products directly. The UK is the test market for a global roll-out. 01 02 03 Practitioner prescribes
Slide 23: International gross margin
GROSS MARGIN International gross margin Estimated international gross margin of ~68% in FY26, seven percentage points above the domestic blend. BLENDED GROSS MARGIN · FY26 ~68% 61% Why the premium exists The 7pp premium reflects channel mix, not pricing. International revenue weights toward practitio
Slide 24: International team
CAPABILITY AND PEOPLE International team 12 international FTE, each a localised connection point, supported by centralised regulatory, supply, science and finance from Australia. CANADA UNITED KINGDOM IRELAND NEW ZEALAND 3 4 3 2 GM, Sales Manager, territory Channel, education, ops and Local commercia
Slide 25: FY27 priorities
FY27 OUTLOOK FY27 priorities Four markets past proof point. The platform, people and channels are in place to scale. FOUR PILLARS OF READINESS FY27 OPERATIONAL PRIORITIES Established markets ● Quebec market unlock and continued Canadian account growth Four markets past proof point, contributing stru
Slide 26: Reviewing strategic opportunities
BEYOND FY27 Reviewing strategic opportunities A disciplined, evidence-led model proven across four jurisdictions. Any new market must clear the bar the first four did: practitioner-led entry, clinical evidence, and disciplined economics. MARKETS PAST PROOF POINT INT'L GROSS MARGIN, FY26 INT'L DISTRIB
Slide 27: Four active markets, one operating model
FY26 INTERNATIONAL MARKETS Four active markets, one operating model Practitioner-only · Clinically backed · Never discounted Biome Australia Limited · ASX: BIO